Cyclerion Therapeutics, Inc. (CYCN)
Upgrades & Downgrades
Latest CYCN news
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
9 August 2022
Cyclerion Therapeutics, Inc. (CYCN) delivered earnings and revenue surprises of 8.82% and 56.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the st...
Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies
17 June 2022
Cyclerion Therapeutics Inc's (NASDAQ: CYCN) preclinical studies demonstrated its lead soluble guanylate cyclase (sGC) stimulator, CY6463, improved cellular energetics and reduced inflammation in precl...
Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinic...
6 June 2022
Topline results to be shared during the clinical trial update platform session
Down 38.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Cyclerion Therapeutics, Inc. (CYCN)
15 December 2021
The heavy selling pressure might have exhausted for Cyclerion Therapeutics, Inc. (CYCN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wa...
Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
26 October 2021
Cyclerion is a spinoff from Ironwood Pharmaceuticals that has had 2 clinical failures but has a unique lead asset in neurodegeneration.
Trending Penny Stocks to Buy Now? 5 to Watch This Week
24 October 2021
Which trending penny stocks are on your watchlist right now? The post Trending Penny Stocks to Buy Now?
Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by ...
22 September 2021
Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with cognitive impairment Company developing lead sGC stimulator, CY6463, in multiple CNS diseases associated with c...
Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit
23 August 2021
Presentation to highlight the potential of early clinical assessment of biomarkers to drive development of Alzheimer's disease therapies Presentation to highlight the potential of early clinical asses...
Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
29 July 2021
Continuing to progress clinical development of CY6463, a first-in-class, CNS-penetrant soluble guanylate cyclase (sGC) stimulator for the treatment of neurological diseases associated with cognitive i...
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants wi...
22 July 2021
Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion's investigational therapeutics Research to be presented highlighting pot...